New Tool to Identify Tumor Heterogeneity Could Help Pave Way for Personalized Cancer Therapies and Help Pathologists Add Value for Oncologists

Ohio State University study shows correlation between genetic variability among cancer cells within tumors and the survival of patients with head-and-neck cancers Anatomic pathologists and clinical laboratories  may gain a tool to identify tumor heterogeneity. This would enable them to ultimately guide personalized cancer therapies if a new method for measuring genetic variability within a tumor and […]
Source: Dark Daily - Category: Laboratory Medicine Authors: Tags: Digital Pathology Instruments & Equipment Laboratory Instruments & Laboratory Equipment Laboratory News Laboratory Operations Laboratory Pathology Laboratory Testing Andrew H. Beck Beth Israel Deaconess Medical Center clinical laboratory Source Type: news

Related Links:

CONCLUSIONS: HPV-positive HNSCC cells are unresponsive to TGFβ. Abrogated TGFβ signaling compromises homologous recombination and shifts reliance on alt-EJ repair that provides a mechanistic basis for sensitivity to PARP inhibitors. The effect of HPV in HNSCC provides critical validation of TGFβ's role in DNA repair proficiency and further raises the translational potential of TGFβ inhibitors in cancer therapy. PMID: 30087144 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract BMI-1 (B-lymphoma Mo-MLV insertion region 1) is a key protein partner in polycomb repressive complex 1 (PRC1) that helps in maintaining the integrity of the complex. It is also a key player in ubiquitination of histone H2A which affects gene expression pattern involved in various cellular processes such as cell proliferation, growth, DNA repair, apoptosis and senescence. In many cancers, Overexpression of BMI1correlates with advanced stages of disease, aggressive clinicopathological behavior, poor prognosis resistance to radiation and chemotherapy. BMI1 is emerging as a key player in EMT, chemo-resistance...
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
CONCLUSION: Both preclinical and clinical studies have demonstrated promising results of the role of celecoxib in the treatment and prevention of cancer - the best outcome was observed in colon, breast, prostate and head and neck cancers. However, more clinical trials providing real evidence-based clinical advances of celecoxib use are needed. PMID: 30073924 [PubMed - as supplied by publisher]
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research
PET scans with the radiotracer F-18 fluorothymidine (FLT) can help determine...Read more on AuntMinnie.comRelated Reading: SNMMI: PET, MRI may predict pediatric brain tumor outcomes FDG-PET/CT beats FLT-PET/CT for differentiated thyroid cancer FLT-PET could help predict outcome in head and neck cancer JNM: FLT-PET aids prognosis of glioma patients FLT-PET helps predicts cancer therapy results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
This study aims to report radiotherapy utilization and fractionation patterns during the first course of cancer treatment.MethodsWe extracted all solid tumor cases from 2004 to 2014 in the National Cancer Data Base, which captures only the first course of treatment. Patients were subcategorized by disease site: breast, central nervous system (CNS), gastrointestinal, genitourinary, gynecologic, head and neck (HN), musculoskeletal, skin, or thoracic. Receipt of therapy was identified (systemic, surgical, or radiation therapy). Radiotherapy was subcategorized as external beam radiation therapy (EBRT) (conventional and stereot...
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
ConclusionClinicians under-report toxicities during and after curative RT in older patients with head and neck or lung cancer. Select toxicities reported by patients early in treatment and clinicians later in treatment were associated with poor tolerance to cancer therapy, providing valuable complementary information.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
This study aims to report radiotherapy utilization and fractionation patterns during the first course of cancer treatment.MethodsWe extracted all solid tumor cases from 2004 to 2014 in the National Cancer Data Base, which captures only the first course of treatment. Patients were subcategorized by disease site: breast, central nervous system (CNS), gastrointestinal, genitourinary, gynecologic, head and neck (HN), musculoskeletal, skin, or thoracic. Receipt of therapy was identified (systemic, surgical, or radiation therapy). Radiotherapy was subcategorized as external beam radiation therapy (EBRT) (conventional and stereot...
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
ConclusionClinicians under-report toxicities during and after curative RT in older patients with head and neck or lung cancer. Select toxicities reported by patients early in treatment and clinicians later in treatment were associated with poor tolerance to cancer therapy, providing valuable complementary information.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
A number of patient reported outcome (PRO) measurement tools have been created to track both quality of life (QoL) and functional outcomes in head and neck cancer (HNC) patients before, during, and after oncologic treatment. Such instruments are vital for the rigorous comparison of various treatments and interventions across clinical studies of HNC and lend to its ease of use for longitudinal repeat assessments. Consistent utilization of PROs may be particularly critical in light of growing concerns that late treatment toxicity may confer a mortality risk with longer follow-up [1 –3].
Source: Oral Oncology - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Head and Neck Cancer | Laboratory Medicine | Middle East Health | Pathology | Study